Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | HPGD | P15428 | 7/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.56 |
| ▸ | GLA | P06280 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | CA3 | P07451 | 2/20 | 0.54 |
| ▸ | CA4 | P22748 | 2/20 | 0.54 |
| ▸ | CA6 | P23280 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446971 | 0.87 | TAS1R3 (0.64) | KDM4EMAPTCASP3SENP7TDP1 | |
| SCHEMBL1287537 | 0.85 | ALDH1A1 (0.66) | KDM4ECYP2D6MAPTCASP3SENP7 | |
| SCHEMBL31367874 | 0.85 | CYP2D6 (0.59) | KDM4ECYP2D6MAPTCASP3SENP7 | |
| SCHEMBL178096 | 0.85 | ALDH1A1 (0.66) | KDM4ECYP2D6MAPTCASP3SENP7 | |
| SCHEMBL177458 | 0.85 | HPGD (0.70) | KDM4ECYP2D6MAPTCASP3SENP7 | |
| SCHEMBL6240000 | 0.84 | CYP2D6 (0.70) | KDM4ECYP2D6MAPTALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL11747973 | 0.84 | ALDH1A1 (0.64) | KDM4ECYP2D6MAPTCASP3SENP7 | |
| SCHEMBL9251599 | 0.84 | CYP2D6 (0.58) | KDM4ECYP2D6MAPTCASP3SENP7 | |
| SCHEMBL8223059 | 0.83 | MAOA (0.67) | KDM4ECYP2D6CYP1A2ALDH1A1HPGD | |
| SCHEMBL1068608 | 0.82 | FLT3 (0.67) | KDM4EMAPTCASP3SENP7TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014063199-A1 | ORGANIC COMPOUNDS | AKAAL PHARMA PTY LTD (AU) | 2014-05-01 | — | — | WO | disclosed |
| US-7524882-B2 | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524882-B2 | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524882-B2 | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1539136-B1 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1539136-B1 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1539136-A4 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050228044-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK SHARP & DOHME CORP. | 2005-10-13 | — | — | US | disclosed |
| EP-1539136-A2 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050113402-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | SUI ZHIHUA (US) | 2005-05-26 | — | — | US | disclosed |
| EP-1296981-B1 | SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040044021-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | SUI ZHIHUA (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004010936-A2 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO., INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| US-6635638-B2 | Treatment of sexual dysfunction, cardiovascular system disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1296981-A2 | SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-24 | — | — | US | disclosed |
| WO-2001087882-A2 | SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
| EP-0733631-B1 | Benzofuran derivates useful as hypoglycemic and hypolidemic agents | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-07-12 | — | — | EP | disclosed |
| US-5723479-A | ANTILIPEMIC AGENTS AND ANTIGLYCEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-03-03 | — | — | US | disclosed |
| EP-0733631-A1 | Benzofuran derivates useful as hypoglycemic and hypolidemic agents | Takeda Chemical Industries, Ltd. (JP) | 1996-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113402-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | KDM4E 1469/4885CYP2D6 485/4885MAPT 3888/4885 |
| US-20040044021-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | KDM4E 1486/4885CYP2D6 456/4885MAPT 3924/4885 |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | KDM4E 1486/4885CYP2D6 456/4885MAPT 3924/4885 |
| US-20050228044-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | PPARD, PPARA, PPARG | KDM4E 3008/4885CYP2D6 1244/4885MAPT 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.